ALLO — Allogene Therapeutics, Inc.

Summary of Allogene Therapeutics Q3 2025 Earnings Call

1. Key Financial Results and Metrics

• Cash Position: As of September 30, 2025, Allogene reported $277.1 million in cash, cash equivalents, and investments, providing a runway into the second half of 2027.
• Expenses: R&D expenses for Q3 totaled $31.2 million (including $2.8 million in noncash stock-based compensation), while G&A expenses were $13.7 million (including $5.9 million in noncash stock-based compensation).
• Net Loss: The company reported a net loss of $41.4 million or $0.19 per share, which includes $8.7 million in noncash stock-based compensation.
• 2025 Guidance: Allogene expects a cash burn of approximately $150 million for the year and full-year GAAP operating expenses of around $230 million, including an estimated $45 million in noncash stock-based compensation.

2. Strategic Updates and Business Highlights

• Clinical Development: Allogene is advancing its allogeneic CAR T-cell therapy platform, focusing on programs like cema-cel in the ALPHA3 trial for lymphoma and ALLO-329 for autoimmune diseases.
• ALPHA3 Trial: The trial has been streamlined to a 2-arm study comparing treatment after standard Fc lymphodepletion versus observation, with over 50 active sites across the U.S. and Canada, and expansion planned for Australia and South Korea.
• Dagger Technology: The Dagger technology is showing promise in the TRAVERSE trial, producing durable responses in metastatic kidney cancer patients.
• Community Integration: The company aims to integrate cell therapies into community healthcare networks, reducing barriers to access and improving patient care delivery.

3. Forward Guidance and Outlook

• Upcoming Milestones: Allogene anticipates pivotal interim data from the ALPHA3 trial and proof-of-concept data from ALLO-329 in the first half of 2026, which could validate the allogeneic platform and influence future clinical strategies.
• Market Positioning: The company believes its allogeneic technology will democratize access to cell therapies, potentially lowering costs and expanding treatment availability.

4. Bad News, Challenges, or Points of Concern

• Clinical Risks: There are inherent risks associated with clinical trials, including the potential for unfavorable outcomes in the upcoming futility analysis for the ALPHA3 trial, which focuses on MRD conversion.
• Competitive Landscape: The company faces competition from other CAR T therapies, including those from Caribou, which recently reported promising results with allogeneic products derived from younger donors.
• Operational Challenges: The complexity of clinical development, particularly in autoimmune indications, presents ongoing challenges in patient recruitment and trial execution.

5. Notable Q&A Insights

• MRD Conversion Focus: During Q&A, it was confirmed that the upcoming futility analysis will primarily focus on MRD conversion, with no additional primary endpoints being evaluated at this stage.
• Enrollment Status: All active sites are reportedly screening and enrolling patients, with a positive response from investigators regarding the streamlined trial design.
• Data Expectations: The initial data readout for ALLO-329 is expected to include biomarker data and early clinical responses, which could provide insights into its efficacy across various autoimmune diseases.
• FDA Interactions: Ongoing communications with the FDA have been productive, with indications that a single-arm approach for CAR-T therapy remains viable, which could facilitate regulatory pathways.

Overall, Allogene Therapeutics is positioned for significant developments in 2026, with a strong financial foundation and promising clinical programs, though it must navigate inherent risks and competitive pressures in the evolving cell therapy landscape.